<DOC>
	<DOCNO>NCT00867815</DOCNO>
	<brief_summary>The primary objective study determine whether use PDE5 inhibitor ( vardenafil , sildenafil , tadalafil ) increase risk development NAION .</brief_summary>
	<brief_title>PDE5 Inhibitor Use Non-arteritic Anterior Ischemic Optic Neuropathy ( NAION )</brief_title>
	<detailed_description>Collected data compare historic data participant case-crossover design .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Neuropathy , Ischemic</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Sudden visual loss 1 eye within 45 day entry study History erectile dysfunction least 1 year prior study enrollment At least 1 dose PDE5 inhibitor ( ) take within year prior onset loss vision Age 40 year old History multiple sclerosis optic neuritis Evidence temporal arteritis History vasculitis collagen vascular disease Previous history NAION</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-arteritic Anterior Ischemic Optic Neuropathy</keyword>
	<keyword>NAION</keyword>
	<keyword>PDE5 inhibitor</keyword>
	<keyword>vardenafil</keyword>
	<keyword>Levitra</keyword>
	<keyword>sildenafil</keyword>
	<keyword>Viagra</keyword>
	<keyword>Tadalafil</keyword>
	<keyword>Cialis</keyword>
	<keyword>acute vision loss</keyword>
	<keyword>vision loss</keyword>
	<keyword>blur vision</keyword>
	<keyword>optic neuropathy</keyword>
	<keyword>erectile dysfunction .</keyword>
</DOC>